Cargando…
Survivin inhibition with YM155 ameliorates experimental pulmonary arterial hypertension
Background: Imbalance between cell proliferation and apoptosis underlies the development of pulmonary arterial hypertension (PAH). Current vasodilator treatment of PAH does not target the uncontrolled proliferative process in pulmonary arteries. Proteins involved in the apoptosis pathway may play a...
Autores principales: | Blanco, Isabel, Marquina, Maribel, Tura-Ceide, Olga, Ferrer, Elisabet, Ramírez, Ana M., Lopez-Meseguer, Manuel, Callejo, Maria, Perez-Vizcaino, Francisco, Peinado, Victor Ivo, Barberà, Joan Albert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176173/ https://www.ncbi.nlm.nih.gov/pubmed/37188265 http://dx.doi.org/10.3389/fphar.2023.1145994 |
Ejemplares similares
-
Updated Perspectives on Pulmonary Hypertension in COPD
por: Blanco, Isabel, et al.
Publicado: (2020) -
The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma
por: Xia, Hongping, et al.
Publicado: (2015) -
Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance
por: Voges, Yvonne, et al.
Publicado: (2016) -
Targeting abundant survivin expression in liposarcoma: subtype dependent therapy responses to YM155 treatment
por: Vay, Christian, et al.
Publicado: (2021) -
Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells
por: Tao, Yan-Fang, et al.
Publicado: (2012)